Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has granted Pfizer Limited approval to conduct a Phase IIIb clinical trial of its investigational migraine treatment Rimegepant (PF-07899801).
The firm had presented the Phase IIIb clinical study protocol No. C4951063 Amendment 1 dated 05 December 2024 for review. The proposal was evaluated during the recent SEC meeting.
“After detailed deliberation, the committee recommended for grant of permission to conduct the trial as presented by the firm,” the SEC noted in its official recommendation.
The committee, however, attached a specific condition related to treatment protocol during the trial:
“The prior medications shall be allowed to the high Menstrual Migraine attack to the subject during the clinical trial.”
Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that has received approval in multiple countries for the acute treatment and preventive management of migraine in adults. It represents a novel class of migraine therapeutics with both abortive and preventive indications.
Also Read: Bharat Serums Gets CDSCO Panel Nod for Phase III Trial of IVIG in Chronic ITP
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.